Health Catalyst (NASDAQ:HCAT) Full Year 2023 Results
Main financial results
-
Revenue: USD 295.9 million (up 7.1% from FY2022).
-
Net loss: USD 118.1 million (loss reduction of 14% compared to FY2022).
-
Loss of US$2.09 per share (improved from loss of US$2.56 in 2022).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Health Catalyst EPS disappoints
Sales were in line with analyst forecasts. Earnings per share (EPS) were 12% lower than analysts expected.
Looking ahead, revenues are expected to increase by an average of 12% per year over the next three years, compared to an 11% growth forecast for the U.S. healthcare services industry.
performance of American healthcare services industry.
The company’s stock price has fallen 21% from a week ago.
risk analysis
need to learn about. two warning signs Found on Health Catalyst.
Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
